annual CFO:
$189.39M+$34.74M(+22.46%)Summary
- As of today (June 30, 2025), PCRX annual cash flow from operations is $189.39 million, with the most recent change of +$34.74 million (+22.46%) on December 31, 2024.
- During the last 3 years, PCRX annual CFO has risen by +$63.67 million (+50.65%).
- PCRX annual CFO is now at all-time high.
Performance
PCRX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
$35.46M+$2.33M(+7.02%)Summary
- As of today (June 30, 2025), PCRX quarterly cash flow from operations is $35.46 million, with the most recent change of +$2.33 million (+7.02%) on March 31, 2025.
- Over the past year, PCRX quarterly CFO has dropped by -$13.64 million (-27.78%).
- PCRX quarterly CFO is now -41.18% below its all-time high of $60.29 million, reached on September 30, 2021.
Performance
PCRX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
$175.75M-$13.64M(-7.20%)Summary
- As of today (June 30, 2025), PCRX TTM cash flow from operations is $175.75 million, with the most recent change of -$13.64 million (-7.20%) on March 31, 2025.
- Over the past year, PCRX TTM CFO has dropped by -$8.88 million (-4.81%).
- PCRX TTM CFO is now -13.78% below its all-time high of $203.84 million, reached on September 30, 2024.
Performance
PCRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PCRX Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | -27.8% | -4.8% |
| 3 y3 years | +50.6% | +15.2% | +21.7% |
| 5 y5 years | +168.6% | +471.2% | +140.0% |
PCRX Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.6% | -34.2% | +85.4% | -13.8% | +39.0% |
| 5 y | 5-year | at high | +168.6% | -41.2% | +326.9% | -13.8% | +404.4% |
| alltime | all time | at high | +370.1% | -41.2% | +267.4% | -13.8% | +350.6% |
PCRX Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $35.46M(+7.0%) | $175.75M(-7.2%) |
| Dec 2024 | $189.39M(+22.5%) | $33.13M(-38.6%) | $189.39M(-7.1%) |
| Sep 2024 | - | $53.92M(+1.3%) | $203.84M(+4.9%) |
| Jun 2024 | - | $53.24M(+8.4%) | $194.36M(+5.3%) |
| Mar 2024 | - | $49.10M(+3.2%) | $184.62M(+19.4%) |
| Dec 2023 | $154.65M(+6.5%) | $47.58M(+7.1%) | $154.65M(+3.7%) |
| Sep 2023 | - | $44.44M(+2.2%) | $149.10M(+1.2%) |
| Jun 2023 | - | $43.50M(+127.4%) | $147.32M(+10.2%) |
| Mar 2023 | - | $19.13M(-54.5%) | $133.63M(-8.0%) |
| Dec 2022 | $145.27M(+15.6%) | $42.04M(-1.4%) | $145.27M(+14.9%) |
| Sep 2022 | - | $42.65M(+43.1%) | $126.45M(-12.2%) |
| Jun 2022 | - | $29.81M(-3.2%) | $144.09M(-0.2%) |
| Mar 2022 | - | $30.78M(+32.6%) | $144.41M(+14.9%) |
| Dec 2021 | $125.72M(+63.2%) | $23.21M(-61.5%) | $125.72M(-15.7%) |
| Sep 2021 | - | $60.29M(+100.1%) | $149.17M(+15.9%) |
| Jun 2021 | - | $30.13M(+149.4%) | $128.66M(+55.2%) |
| Mar 2021 | - | $12.08M(-74.1%) | $82.91M(+7.6%) |
| Dec 2020 | $77.03M(+9.2%) | $46.67M(+17.3%) | $77.03M(+36.9%) |
| Sep 2020 | - | $39.78M(-354.6%) | $56.27M(+61.5%) |
| Jun 2020 | - | -$15.62M(-351.7%) | $34.84M(-52.4%) |
| Mar 2020 | - | $6.21M(-76.0%) | $73.23M(+3.8%) |
| Dec 2019 | $70.52M(+44.3%) | $25.90M(+41.1%) | $70.52M(+7.1%) |
| Sep 2019 | - | $18.35M(-19.4%) | $65.84M(+2.7%) |
| Jun 2019 | - | $22.76M(+550.6%) | $64.11M(+16.4%) |
| Mar 2019 | - | $3.50M(-83.5%) | $55.06M(+12.7%) |
| Dec 2018 | $48.87M(+174.8%) | $21.22M(+27.6%) | $48.87M(+9.6%) |
| Sep 2018 | - | $16.63M(+21.3%) | $44.58M(+77.3%) |
| Jun 2018 | - | $13.71M(-609.9%) | $25.14M(+66.6%) |
| Mar 2018 | - | -$2.69M(-115.9%) | $15.09M(-15.2%) |
| Dec 2017 | $17.79M | $16.93M(-703.0%) | $17.79M(-2.3%) |
| Sep 2017 | - | -$2.81M(-176.8%) | $18.20M(-44.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $3.66M(>+9900.0%) | $32.70M(-10.6%) |
| Mar 2017 | - | $6000.00(-100.0%) | $36.58M(+9.3%) |
| Dec 2016 | $33.45M(+19.4%) | $17.35M(+48.5%) | $33.45M(+1.1%) |
| Sep 2016 | - | $11.68M(+54.9%) | $33.10M(+26.7%) |
| Jun 2016 | - | $7.54M(-341.6%) | $26.13M(+1.4%) |
| Mar 2016 | - | -$3.12M(-118.4%) | $25.77M(-8.0%) |
| Dec 2015 | $28.02M(+5.5%) | $16.99M(+260.1%) | $28.02M(+8.8%) |
| Sep 2015 | - | $4.72M(-34.3%) | $25.75M(-12.4%) |
| Jun 2015 | - | $7.18M(-925.1%) | $29.39M(-3.4%) |
| Mar 2015 | - | -$870.00K(-105.9%) | $30.43M(+14.6%) |
| Dec 2014 | $26.56M(-160.6%) | $14.72M(+76.1%) | $26.56M(+437.7%) |
| Sep 2014 | - | $8.36M(+1.7%) | $4.94M(-137.3%) |
| Jun 2014 | - | $8.22M(-273.5%) | -$13.26M(-61.9%) |
| Mar 2014 | - | -$4.74M(-31.4%) | -$34.78M(-20.7%) |
| Dec 2013 | -$43.84M(-37.5%) | -$6.90M(-29.8%) | -$43.84M(-24.6%) |
| Sep 2013 | - | -$9.84M(-26.1%) | -$58.12M(-2.3%) |
| Jun 2013 | - | -$13.31M(-3.5%) | -$59.45M(-10.4%) |
| Mar 2013 | - | -$13.79M(-34.9%) | -$66.37M(-5.4%) |
| Dec 2012 | -$70.13M(+126.2%) | -$21.18M(+89.5%) | -$70.13M(+24.0%) |
| Sep 2012 | - | -$11.18M(-44.7%) | -$56.55M(+5.0%) |
| Jun 2012 | - | -$20.23M(+15.3%) | -$53.86M(+20.9%) |
| Mar 2012 | - | -$17.55M(+131.0%) | -$44.56M(+43.7%) |
| Dec 2011 | -$31.00M(+24.6%) | -$7.60M(-10.6%) | -$31.00M(+6.0%) |
| Sep 2011 | - | -$8.49M(-22.2%) | -$29.24M(+5.7%) |
| Jun 2011 | - | -$10.92M(+174.0%) | -$27.66M(+9.5%) |
| Mar 2011 | - | -$3.99M(-31.7%) | -$25.27M(+1.6%) |
| Dec 2010 | -$24.88M(+19.4%) | -$5.84M(-15.5%) | -$24.88M(+30.7%) |
| Sep 2010 | - | -$6.91M(-19.0%) | -$19.04M(+57.0%) |
| Jun 2010 | - | -$8.53M(+137.2%) | -$12.13M(+237.2%) |
| Mar 2010 | - | -$3.60M | -$3.60M |
| Dec 2009 | -$20.84M(-28.6%) | - | - |
| Dec 2008 | -$29.19M | - | - |
FAQ
- What is Pacira BioSciences annual cash flow from operations?
- What is the all time high annual CFO for Pacira BioSciences?
- What is Pacira BioSciences annual CFO year-on-year change?
- What is Pacira BioSciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Pacira BioSciences?
- What is Pacira BioSciences quarterly CFO year-on-year change?
- What is Pacira BioSciences TTM cash flow from operations?
- What is the all time high TTM CFO for Pacira BioSciences?
- What is Pacira BioSciences TTM CFO year-on-year change?
What is Pacira BioSciences annual cash flow from operations?
The current annual CFO of PCRX is $189.39M
What is the all time high annual CFO for Pacira BioSciences?
Pacira BioSciences all-time high annual cash flow from operations is $189.39M
What is Pacira BioSciences annual CFO year-on-year change?
Over the past year, PCRX annual cash flow from operations has changed by +$34.74M (+22.46%)
What is Pacira BioSciences quarterly cash flow from operations?
The current quarterly CFO of PCRX is $35.46M
What is the all time high quarterly CFO for Pacira BioSciences?
Pacira BioSciences all-time high quarterly cash flow from operations is $60.29M
What is Pacira BioSciences quarterly CFO year-on-year change?
Over the past year, PCRX quarterly cash flow from operations has changed by -$13.64M (-27.78%)
What is Pacira BioSciences TTM cash flow from operations?
The current TTM CFO of PCRX is $175.75M
What is the all time high TTM CFO for Pacira BioSciences?
Pacira BioSciences all-time high TTM cash flow from operations is $203.84M
What is Pacira BioSciences TTM CFO year-on-year change?
Over the past year, PCRX TTM cash flow from operations has changed by -$8.88M (-4.81%)